XML 137 R122.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Reporting - Reconciliation of Adjusted EBITDA (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2024
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]                      
Revenue $ 646,542 $ 621,401 $ 647,145 $ 639,653 $ 556,055 $ 511,015 $ 469,136 $ 427,690 $ 2,554,741 [1] $ 1,963,896 [1] $ 1,352,013 [1]
Depreciation and amortization expenses                 118,370 123,415 67,195
Interest income                 (5,544) (5,256) (1,369)
Interest expense                 24,722 54,205 15,572
Gain (loss) from equity method investees                 3,441 (1,290) (4,569)
Benefit from income taxes                 (1,413) (89,365) (43,376)
Change in tax receivables agreement liability                 173 61,982 45,950
Net loss attributable to common shareholders of Evolent Health, Inc. - basic (30,615) (31,231) (6,383) (25,225) (41,395) (33,196) (41,411) (26,258) (93,454) (142,260) (19,164)
Net loss attributable to common shareholders of Evolent Health, Inc. - diluted $ (30,615) $ (31,231) $ (6,383) $ (25,225) $ (41,395) $ (33,196) $ (41,411) $ (26,258) (93,454) (142,260) (19,164)
Total compensation expense by financial statement line item                 39,746 40,501 33,981
Amortization of contract cost assets                 4,798 10,944 23,056
Severance and termination benefits                      
Segment Reporting Information [Line Items]                      
Restructuring charges                 2,900 1,500 13,300
Cost of revenue                      
Segment Reporting Information [Line Items]                      
Total compensation expense by financial statement line item                 4,582 1,662 4,387
Acquisition related costs                     1,600
Amortization of contract cost assets                     100
Selling, general and administrative expenses                      
Segment Reporting Information [Line Items]                      
Total compensation expense by financial statement line item                 35,164 38,839 29,594
Acquisition related costs                 2,900 15,100 10,100
Repositioning costs                 10,600 35,200 0
Reportable segment                      
Segment Reporting Information [Line Items]                      
Revenue                 2,554,741 1,963,896 1,352,013
Medical expense and device costs                 1,813,052 1,143,499 725,036
Adjusted cost of revenue after medical expense and device costs                 369,754 358,265 304,326
Adjusted selling, general and administrative expenses                 211,475 267,454 216,320
Depreciation and amortization expenses                 118,370 123,415 67,195
Interest income                 (5,544) (5,256) (1,369)
Interest expense                 24,722 54,205 15,572
Gain (loss) from equity method investees                 3,441 (1,290) (4,569)
Benefit from income taxes                 (1,413) (89,365) (43,376)
Change in tax receivables agreement liability                 173 61,982 45,950
Other segment items                 $ 114,165 $ 193,247 $ 46,092
[1] See Note 19 for amounts attributable to unconsolidated related parties included in these line items.